Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

Key Terms

non-systemic medical

An adjective used in medical and regulatory contexts to describe a drug, treatment, or exposure that acts only in a specific part of the body or local area rather than traveling through the bloodstream to affect the whole body. Like applying a patch to a single spot instead of taking a pill that travels everywhere, non-systemic products are relevant to investors because they can imply different safety profiles, regulatory pathways, and market niches compared with systemic therapies.

atopic dermatitis medical

A chronic inflammatory skin condition, often called eczema, that causes dry, itchy, red patches and recurring flare-ups; think of it as a persistent rash that can come and go over a person’s life. It matters to investors because its chronic nature and large patient population create steady demand for treatments, influence drug development and approval decisions, affect healthcare costs and reimbursement, and can drive revenue and valuation shifts for companies working on therapies and diagnostics.

systemic immunosuppression medical

A widespread weakening of the body's immune defenses that affects the whole body rather than a single organ or tissue. It can result from certain drugs, medical treatments, or diseases and increases the risk of infections and complications; think of it like turning down a building's whole security system so every entrance becomes more vulnerable. For investors, systemic immunosuppression is relevant to drug safety profiles, regulatory review, market labeling, clinical trial design, and potential liability or follow‑on costs.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Turn Therapeutics Returns to Nasdaq to Highlight Its Progress Since Its October 2025 Direct Listing

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Founder and Chief Executive Officer, will ring the Nasdaq Closing Bell on August 10, 2026, along with members of the Turn Therapeutics management team, at Nasdaq's invitation to mark its progress to date.

"We're honored that Nasdaq invited us back to share our story," said Bradley Burnam, Founder and Chief Executive Officer of Turn Therapeutics. "Over the past year we've made meaningful progress, but what I'm most proud of is that we got here by refusing to believe there was only one way to build a biotech company. Turn Therapeutics was founded on the principle that patients deserve targeted, localized therapies rather than systemic treatment whenever possible. We challenged conventional thinking in our science, in how we built the company, and in how we came to the public markets. I hope our story reminds other entrepreneurs that 'the usual way' isn't the only way."

Overview of Event Details

Nasdaq Bell Ringing Ceremony

• Event Date: Monday, August 10, 2026
• Time: The Closing Bell ceremony will be broadcast live beginning at 3:45 p.m. ET
• Location: Nasdaq MarketSite, Times Square, New York
• Event Livestream Link: https://www.nasdaq.com/marketsite/bell-ringing-ceremony

About Turn Therapeutics

Turn Therapeutics is a clinical-stage biotechnology company focused on developing targeted, localized therapies for inflammatory and infectious skin diseases. GX-03 is Turn Therapeutics' lead investigational topical candidate being developed as a targeted, non-systemic treatment for atopic dermatitis, designed to deliver biologic-level efficacy without the trade-offs of injectable administration or systemic immunosuppression. For more information, visit www.turntherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including statements regarding clinical development plans, optimization of enrollment criteria and endpoints, interpretation of interim clinical observations, expected trial timing, regulatory interactions, and the therapeutic potential of GX-03. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Turn Therapeutics’ current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the success of development programs, the availability of additional financing, and the Company’s ability to execute its strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Turn Therapeutics in general, see the risk disclosures in the Company’s filings with the SEC. All such forward-looking statements speak only as of the date they are made, and Turn Therapeutics undertakes no obligation to update or revise these statements, whether as a result of new information, future events, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260728763249/en/

Turn Therapeutics Investor & Media Contact
Sasha Damouni
The Damouni Group
Sasha@damounigroup.com

Source: Turn Therapeutics Inc.